Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026

REGN vs ALNY: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

REGN Wins Head-to-Head Institutional Verdict (3–3 across 6 Pillars · 6–4 Matrix Metrics)

REGN Overall Winner 6-Pillar Tally: REGN 3 – 3 ALNY Matrix Metrics: REGN 6 – 4 ALNY

As of Nov 19, 2026, Regeneron Pharmaceuticals Inc (REGN) is the stronger overall head-to-head candidate over Alnylam Pharmaceuticals, Inc. (ALNY) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Growth & Scale, Balance Sheet & Cash Flow, Options & Positioning). REGN carries a Unified Composite Score of 42.6/100 (HOLD) at $923.34 (14.9x Forward P/E, 30.4% operating margin), whereas ALNY carries 50.9/100 (HOLD) at $147.82 (15.0x Forward P/E, 19.5% operating margin).

  • Composite vs. Pillar Nuance: While ALNY currently prints a higher short-term Unified Composite Score (50.9/100 HOLD vs. REGN 42.6/100 HOLD), REGN captures the overall institutional head-to-head verdict (6–4 matrix metrics and 3–3 across the 6 pillars) due to superior fundamental profitability (30.4% vs. 19.5% operating margin) and revenue trajectory (+36.3% vs. +16.7% YoY).
  • Technical & Structure Timing Caution: REGN trades in a Markup technical trend (CONSOLIDATION options phase, RSI 57.9); meanwhile ALNY is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 28.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About REGN vs ALNY
REGN NASDAQ Head-to-Head Winner
Regeneron Pharmaceuticals Inc
Pharmaceutical Preparations
$923.34
-2.35% 1D
Market Cap $97.8B
TTM Revenue $16.9B
Forward P/E 14.9x
Beta / 30D Vol 0.32β · 55% Vol
Unified Composite Score
42.6 / 100 HOLD
Tech 19.0 Fund 45.0 Flow 68.0 Mom 56.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (4.5% over 20 days), RSI 58
RSI-14: 57.9 · SMA20: $907.12 · SMA50: $826.97
ALNY NASDAQ
Alnylam Pharmaceuticals, Inc.
Pharmaceutical Preparations
$147.82
-1.06% 1D
Market Cap $20.0B
TTM Revenue $5.01B
Forward P/E 15.0x
Beta / 30D Vol 0.55β · 94% Vol
Unified Composite Score
50.9 / 100 HOLD
Tech 45.0 Fund 64.0 Flow 67.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -11.8%), weak momentum, RSI 28
RSI-14: 28.0 · SMA20: $172.23 · SMA50: $210.88

6-Pillar Scorecard Institutional Category Breakdown (REGN 3 – 3 ALNY)

Columns: Metric · REGN · ALNY
1. Valuation Multiples ALNY
Forward P/E 14.9x 15.0x
Trailing P/E 20.9x 7.5x
PEG Ratio 1.15x 0.21x
EV / Revenue 5.7x 3.9x
2. Growth & Scale REGN
Revenue Growth (YoY) +36.3% +16.7%
Earnings Growth (YoY) +35.5% +633.5%
TTM Revenue (USD) $16.9B $5.01B
Market Cap $97.8B $20.0B
3. Profitability & Quality ALNY
Gross Margin 46.7% 77.3%
Operating Margin 30.4% 19.5%
Net Profit Margin 28.5% 52.8%
Return on Equity (ROE) 14.9% 138.1%
4. Balance Sheet & Cash Flow REGN
Cash Generation (TTM) $3.63B $752M
Cash Flow Margin 21.5% 15.0%
Net Cash / Leverage $952M Net Cash $492M Net Cash
Dividend Yield 0.39% None (0.00%)
5. Options & Positioning REGN
Options Structure Phase CONSOLIDATION BREAKDOWN
Current IV / %ile 35.5% (6th %ile) 49.9% (34th %ile)
Put/Call OI Skew 0.47x (Call-Skewed) 0.85x (Call-Skewed)
OBV Trend / Tech Phase ACCUMULATION · Markup DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat ALNY
OpEx & R&D Intensity 16.3% of Rev ($2.75B) 57.8% of Rev ($2.90B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat High-Margin Pricing Power Moat High-Margin Pricing Power Moat
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: REGN (6) vs ALNY (4)
Institutional Metric REGN ALNY Criterion Row Edge
Market Capitalization
Scale
$97.8B $20.0B Larger Scale REGN
Trailing P/E Ratio
Valuation
20.9x 7.5x Lower Multiple ALNY
Forward P/E Ratio
Valuation
14.9x 15.0x Lower Multiple REGN
Revenue Growth (YoY)
Growth
+36.3% +16.7% Higher Growth REGN
Operating Margin (TTM)
Profitability
30.4% 19.5% Higher Margin REGN
Net Profit Margin
Profitability
28.5% 52.8% Higher Margin ALNY
Return on Equity (ROE)
Capital Efficiency
14.9% 138.1% Higher ROE ALNY
52-Week Range Position
Momentum
83% ($592–$992) 0% ($147–$477) Stronger Trend REGN
Beta / 30D Volatility
Risk Regime
0.32β · 55% Vol 0.55β · 94% Vol Lower Realized Risk REGN
Unified Institutional Score
Composite Signal
42.6 / 100 (HOLD) 50.9 / 100 (HOLD) Higher Composite ALNY
Trailing 12M Revenue (USD)
Operating Scale
$16.9B $5.01B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
46.7% 77.3% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
1.15x PEG · 5.7x EV/Rev 0.21x PEG · 3.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$3.63B ($952M Net Cash) $752M ($492M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon REGN +48.94 pp
REGN: +14.61% · ALNY: -34.33%
3M Horizon REGN +48.13 pp
REGN: +10.71% · ALNY: -37.42%
6M Horizon REGN +94.5 pp
REGN: +43.69% · ALNY: -50.81%
1Y Horizon REGN +95.33 pp
REGN: +27.3% · ALNY: -68.03%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period REGN Revenue ALNY Revenue REGN Op. Margin ALNY Op. Margin Margin Leader
FY2018 $5.15B $70M 49.3% -1087.6% REGN
FY2019 $6.56B $220M 33.7% -427.5% REGN
FY2020 $8.50B $490M 42.1% -168.1% REGN
FY2021 $16.1B $840M 55.7% -83.9% REGN
FY2022 $12.2B $1.04B 38.9% -75.7% REGN
FY2023 $13.1B $1.83B 30.9% -15.4% REGN
FY2024 $14.2B $2.25B 28.1% -7.9% REGN
FY2025 $14.3B $3.71B 24.9% 13.5% REGN

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
REGN CONSOLIDATION
55d in phase · OBV ACCUMULATION
Current IV 35.5%
IV Percentile 6th %ile
Put/Call OI Skew 0.47x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact REGN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ALNY BREAKDOWN
55d in phase · OBV DISTRIBUTION
Current IV 49.9%
IV Percentile 34th %ile
Put/Call OI Skew 0.85x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact ALNY Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $952.40 · IV 33.5%

REGN vs. ALNY: Simulated 5-Day Option Payoffs & Capital Efficiency

Compare 100 shares of REGN ($95,240) vs. ALNY ($15,973) against risk-defined 5-day vertical and put-wall option structures.

REGN Spot $952.40 · IV 33.5%
REGN Options Simulator →
5-DAY BULLISH SWING Liq C

Dec 18 $950 / $1,000 Bull Call Spread

Buy 1x $950C · Sell 1x $1,000C · 31d

Net Entry $2,387 Debit
T+5d @ +5% Move +$891 (+37%)
Max Risk / Buffer $2,387 Capped
5d Edge & Liquidity 0.8x R:R · Liq C
Simulate 5-Day Payoff →
PUT-WALL MONTHLY INCOME Liq C

Jan 15 '27 $880 / $820 Bull Put Spread

Sell 1x $880P · Buy 1x $820P · 59d

Net Entry $1,367 Credit
Max Credit / Yield +$1,367 (+29.5% RoM)
Max Risk / Buffer -9.0% Cushion ($4,633 Mgn)
5d Edge & Liquidity 75% PoP · Liq C
Simulate 5-Day Payoff →
ALNY Spot $159.73 · IV 50.9%
ALNY Options Simulator →
5-DAY BULLISH SWING Liq B

Dec 18 $165 / $180 Bull Call Spread

Buy 1x $165C · Sell 1x $180C · 32d

Net Entry $395 Debit
T+5d @ +5% Move +$161 (+41%)
Max Risk / Buffer $395 Capped
5d Edge & Liquidity 0.9x R:R · Liq B
Simulate 5-Day Payoff →
PUT-WALL MONTHLY INCOME Liq B

Dec 18 $145 / $135 Bull Put Spread

Sell 1x $145P · Buy 1x $135P · 32d

Net Entry $165 Credit
Max Credit / Yield +$165 (+19.8% RoM)
Max Risk / Buffer -10.3% Cushion ($835 Mgn)
5d Edge & Liquidity 79% PoP · Liq B
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
REGN Moat Profile High-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $97.8B market capitalization and 30.4% operating margin.
OpEx & R&D Reinvestment 16.3% of Rev ($2.75B)
90D Engineering Disclosures 0 Published
ALNY Moat Profile High-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $20.0B market capitalization and 19.5% operating margin.
OpEx & R&D Reinvestment 57.8% of Rev ($2.90B)
90D Engineering Disclosures 0 Published

Investor FAQ REGN vs ALNY Key Questions & Quantitative Answers

As of Nov 19, 2026, Regeneron Pharmaceuticals Inc (REGN) is the stronger overall head-to-head candidate over Alnylam Pharmaceuticals, Inc. (ALNY) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Growth & Scale, Balance Sheet & Cash Flow, Options & Positioning). REGN carries a Unified Composite Score of 42.6/100 (HOLD) at $923.34 (14.9x Forward P/E, 30.4% operating margin), whereas ALNY carries 50.9/100 (HOLD) at $147.82 (15.0x Forward P/E, 19.5% operating margin). Composite vs. Pillar Nuance: While ALNY currently prints a higher short-term Unified Composite Score (50.9/100 HOLD vs. REGN 42.6/100 HOLD), REGN captures the overall institutional head-to-head verdict (6–4 matrix metrics and 3–3 across the 6 pillars) due to superior fundamental profitability (30.4% vs. 19.5% operating margin) and revenue trajectory (+36.3% vs. +16.7% YoY). Technical & Structure Timing Caution: REGN trades in a Markup technical trend (CONSOLIDATION options phase, RSI 57.9); meanwhile ALNY is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 28.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

REGN leads the Growth & Scale pillar: REGN posts +36.3% YoY revenue growth and +35.5% YoY earnings growth on $16.9B TTM revenue (46.7% gross margin, 30.4% operating margin), compared with ALNY at +16.7% YoY revenue growth and +633.5% YoY earnings growth on $5.01B TTM revenue (77.3% gross margin, 19.5% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), REGN cumulative revenue shifted +178.4% while ALNY shifted +5200.0%. In operating R&D and SG&A reinvestment, REGN deploys 16.3% of Rev ($2.75B) (0 90-day corporate R&D disclosures) versus 57.8% of Rev ($2.90B) (0 disclosures) for ALNY.

ALNY screens cheaper on headline valuation multiples. REGN trades at 14.9x Forward P/E, 20.9x Trailing P/E, 1.15x PEG, and 5.7x EV/Revenue (21.5% FCF margin), whereas ALNY trades at 15.0x Forward P/E, 7.5x Trailing P/E, 0.21x PEG, and 3.9x EV/Revenue (15.0% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against REGN (14.9% ROE) versus ALNY (138.1% ROE) capital efficiency.

In options market volatility and institutional positioning, REGN carries 35.5% implied volatility (6th %ile, Compressed (<25th %ile)), a 0.47x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.32β · 55% Vol realized risk). By comparison, ALNY carries 49.9% implied volatility (34th %ile, Balanced (25th–60th %ile)), a 0.85x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (0.55β · 94% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.